{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:44:59Z","timestamp":1762098299413},"reference-count":21,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2007,6,6]],"date-time":"2007-06-06T00:00:00Z","timestamp":1181088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The effect of innovative medicines and surgical interventions on the decline of (cardiovascular) mortality is often called into question. The increase in general economic prosperity is often seen as the main reason for the continuous increase in life expectancy. The purpose of this study is to investigate the extent to which mortality from cardiovascular diseases has been affected by pharmaceuticals and other medical interventions over the last 30 years in Germany.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Main outcome measures were the time series of direct method death rates (DMDR) of cardiovascular and non\u2010cardiovascular mortalities. To control for socioeconomic and secular trends the difference between both time series was calculated. The impact of interventions on mortality was analysed by developing two linear regression models: The onset model analyses whether the introduction of interventions influences mortality or not. The consumption model estimates the quantitative impact of interventions in two phases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Cardiovascular mortality as a percentage of total mortality fell from 40 to 38% over the study period. All investigated interventions had statistically significant effects on the decline of cardiovascular diseases, which is expressed by the standardised regression coefficient: onset model: preventive behaviour index (PBI) \u22128.3, angioplasty\/CABG \u22120.6, antithrombotic agents \u22121.5, diuretics \u22120.9, beta\u2010blockers \u22121.0, calcium channel blockers \u22120.8 and ACE inhibitors \u22121.1 (all interventions <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01); consumption model: innovative drugs phase I \u22127.5 (<jats:italic>p<\/jats:italic>\u2009=\u20090.017), innovative drugs phase II \u22126.9 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), PBI \u221213.1 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and angioplasty\/CABG \u22129.9 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>All innovative drug classes and surgical interventions had a positive effect on the decline of cardiovascular mortality. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1428","type":"journal-article","created":{"date-parts":[[2007,6,6]],"date-time":"2007-06-06T11:17:02Z","timestamp":1181128622000},"page":"1167-1176","source":"Crossref","is-referenced-by-count":4,"title":["The impact of pharmaceuticals on the decline of cardiovascular mortality in Germany"],"prefix":"10.1002","volume":"16","author":[{"given":"Bertram","family":"H\u00e4ussler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Schiffhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Gothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Hempel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,6,6]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"McKeownT.The role of medicine: dream mirage or nemesis?Nuffield Provincial Hospitals Trust 1976."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.309.6969.1657"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.309.6962.1099"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.00149"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.16.5.412"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200018001-00006"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200422002-00004"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043798-199606000-00002"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.81.4.380"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.13.1511"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000118498.35499.B2"},{"issue":"2","key":"e_1_2_1_13_2","first-page":"384","article-title":"Do (more and better) drugs keep people out of hospitals?","volume":"86","author":"Lichtenberg FR","year":"1996","journal-title":"Am Econ Rev, American Economic Association"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.20.5.241"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jom.0000158724.28302.ac"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10754-005-6601-7"},{"key":"e_1_2_1_17_2","volume-title":"The Life Table and Its Applications","author":"Chiang CL","year":"1984"},{"key":"e_1_2_1_18_2","unstructured":"BruckenbergerE. 14.Herzbericht 2001 mit Transplantationschirurgie(Hannover: Nieders\u00e4chsisches Ministerium f\u00fcr Frauen Arbeit und Soziales)."},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90129-5"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/29.5.891"},{"issue":"8934","key":"e_1_2_1_21_2","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"issue":"7","key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jama.1997.03540310033031","article-title":"The recent decline in mortality from coronary heart disease, 1980\u20101990.The effects of secular trends in risk factors and treatment","volume":"277","author":"Hunink GM","year":"1997","journal-title":"JAMA"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1428","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:39:07Z","timestamp":1700008747000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,6]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1002\/pds.1428"],"URL":"https:\/\/doi.org\/10.1002\/pds.1428","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,6]]}}}